Trump orders ibogaine and other psychedelics on fast track at FDA
Alcoholism & Drug Abuse Weekly April 24, 2026 Peer reviewed DOI: 10.1002/adaw.34891 via OpenAlex
Summary
President Trump signed an executive order on April 17 directing the FDA to create a pathway for patients to access investigational psychedelic drugs, such as ibogaine. The order addresses treatment-resistant mental illness and mandates the HHS to allocate $50 million through the ARPA-H program to support state investments in research on psychedelics for individuals with serious mental health issues.
Study at a glance
| Key finding | The executive order aims to improve access to investigational psychedelic drugs for patients with treatment-resistant mental illness. |
|---|
Abstract
On April 17, President Donald Trump signed an executive order directing the U.S. Food and Drug Administration (FDA) to “establish a pathway for eligible patients to access investigational psychedelic drugs, including ibogaine compounds.” While citing the need for solutions to treatment‐resistant mental illness, Trump also required the U.S. Department of Health and Human Services (HHS) to allocate $50 million through the Advanced Research Projects for Health (ARPA‐H) program to match investments made by state governments to advance research into psychedelic programs for populations with serious mental illness.